Andy M. Zuniga

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Justin K. Huang, P. Mandal, Jason P. Burke, 2020, Cancer Research.

Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer.

G. Genovese, C. Bristow, S. Seth, 2021, Gastroenterology.

Abstract 3277: IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme

F. Mseeh, T. Heffernan, Ningping Feng, 2019, Clinical Research (Excluding Clinical Trials).